Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.59)
# 235
Out of 5,150 analysts
126
Total ratings
54.31%
Success rate
29.89%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Maintains: Buy | $8 → $5 | $1.17 | +327.35% | 8 | Mar 2, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $5 → $4 | $0.38 | +964.68% | 9 | Feb 26, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $6.65 | +170.68% | 2 | Feb 20, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $25.82 | +70.41% | 6 | Feb 10, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 | $26.84 | +41.58% | 9 | Feb 10, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.25 | +380.00% | 4 | Feb 6, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $28.77 | +94.65% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $11.06 | +135.08% | 11 | Oct 31, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $76.20 | +15.49% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $7.77 | +54.44% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $16 | $1.26 | +1,169.84% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $12.96 | +332.10% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.57 | +75.05% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.20 | +92.49% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $28.71 | +11.48% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $8.93 | +303.14% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $563.87 | -95.03% | 1 | Aug 22, 2023 |
Immunic
Mar 2, 2026
Maintains: Buy
Price Target: $8 → $5
Current: $1.17
Upside: +327.35%
FibroBiologics
Feb 26, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $0.38
Upside: +964.68%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $6.65
Upside: +170.68%
Zenas BioPharma
Feb 10, 2026
Reiterates: Buy
Price Target: $44
Current: $25.82
Upside: +70.41%
Kodiak Sciences
Feb 10, 2026
Reiterates: Buy
Price Target: $38
Current: $26.84
Upside: +41.58%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.25
Upside: +380.00%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $28.77
Upside: +94.65%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.06
Upside: +135.08%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $76.20
Upside: +15.49%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $7.77
Upside: +54.44%
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $1.26
Upside: +1,169.84%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $12.96
Upside: +332.10%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $4.57
Upside: +75.05%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.20
Upside: +92.49%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $28.71
Upside: +11.48%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $8.93
Upside: +303.14%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $563.87
Upside: -95.03%